7 completed, 2 recruiting. 9 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 7, Recruiting 2 |
| Phase 2 | 3 | Recruiting 2, Completed 1 |
Follow Paresthesia: new trials by email Literature Review of Paresthesia trials Research Report on Paresthesia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ozone Treatment in Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy Ozone therapy, Oxygen (placebo) - Chemotherapy Induced Peripheral Neuropathy (CIPN), Paresthesia | Phase 2 / Phase 3 | Recruiting | Bernardino Clavo, MD, PhD | 42 | 2025-02-07 | 2026-09-18 |
| Gut Microbiome Profiles in Patients With Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544). Ozone therapy, Oxygen (placebo) - Chemotherapy Induced Peripheral Neuropathy (CIPN), Paresthesia | Phase 2 / Phase 3 | Recruiting | Bernardino Clavo, MD, PhD | 42 | 2025-02-07 | 2026-09-25 |
| Study of Acetyllevocarnitine Hydrochloride Tablets in Chinese Patients With Paresthesias Caused by DPN Acetyllevocarnitine Hydrochloride Tablets, Placebo - Diabetic Peripheral Neuropathy (DPN), Paresthesia | Phase 3 | Completed | Haisco Pharmaceutical Group Co., Ltd. | 516 | 2020-07-23 | 2022-04-08 |
| Using Intranasal Midazolam (INM) and Lidocaine for Uncooperative Children Midazolam, Lidocaine-Midazolam, Placebo - Burning Nose | Phase 2 / Phase 3 | Completed | Latakia University | 63 | 2017-06-01 | 2018-11-05 |
| Prevention of Oxaliplatin-induced Neuropathic Pain by a Specific Diet Polyamines depleted diet, associating Polydol® cans and predefined menus low in polyamines - Neuropathy, Digestive Cancer System | Phase 3 | Completed | University Hospital, Clermont-Ferrand | 80 | 2013-02-02 | 2017-07-11 |
| Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. Xaliproden (SR57746A), Placebo, Oxaliplatin - Metastases, Colorectal Neoplasms | Phase 3 | Completed | Sanofi | 879 | 2005-12-01 | 2016-05-04 |
| XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy SR57746A - Metastases, Colorectal Neoplasms | Phase 3 | Completed | Sanofi | 620 | 2002-07-01 | 2006-09-13 |
| Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel BNP7787, Placebo - Breast Neoplasms, Breast Diseases | Phase 3 | Completed | BioNumerik Pharmaceuticals, Inc. | 764 | 2001-09-01 | 2022-07-13 |
| Phase III Randomized, Double-Blind, Placebo-Controlled Study of Mexiletine for Painful Diabetic Neuropathy mexiletine - Pain, Diabetic Neuropathies | Phase 3 | Completed | National Center for Research Resources (NCRR) | 40 | 1993-03-01 | 2005-06-24 |
Neoplasm Metastasis (3) · Neurotoxicity Syndromes (3) · Anxiety Disorders (2) · Colorectal Neoplasms (2) · Depression (2) · Hypesthesia (2) · Breast Diseases (1) · Breast Neoplasms (1) · Diabetic Neuropathies (1) · Digestive System Neoplasms (1) · Hyperalgesia (1) · Mental Disorders (1) · Neoplasms (1) · Neurologic Manifestations (1)
Nervous System Diseases (9) · Pathological Conditions, Signs and Symptoms (9) · Sensation Disorders (9) · Signs and Symptoms (9) · Somatosensory Disorders (9) · Neurologic Manifestations (8) · Neoplasms by Site (4) · Pathologic Processes (4) · Chemically-Induced Disorders (3) · Digestive System Diseases (3) · Neoplasms (3) · Neoplastic Processes (3) · Poisoning (3) · Behavior (2) · Behavioral Symptoms (2)
Oxygen (2) · xaliproden (2) · 2,2'-dithiodiethanesulfonic acid (1) · Fluorouracil (1) · Leucovorin (1) · Mexiletine (1) · Midazolam (1) · Oxaliplatin (1) · Polyamines (1)
Bernardino Clavo, MD, PhD (2) · Sanofi (2) · BioNumerik Pharmaceuticals, Inc. (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · Latakia University (1) · National Center for Research Resources (NCRR) (1) · University Hospital, Clermont-Ferrand (1)
Spain (3) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · Chile (1) · China (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Poland (1) · Portugal (1) · Syria (1) · United Kingdom (1)
Bernardino Clavo, MD, PhD (2) · Himar Fabelo, BSc, PhD (1) · Jacob Lorenzo-Morales, Prof (1) · Lixin Guo (1) · Nabih Raslan, Dr. (1) · Tulio Bertorini (1) · Walaa Khalil, Dr. (1)
PMID 30679026, PMID 31378656, PMID 36606664, PMID 25833669, PMID 27739142, PMID 41572235